GMAPX
Price
$35.32
Change
-$0.14 (-0.39%)
Updated
Jul 31 closing price
Net Assets
1.01B
VSMAX
Price
$141.38
Change
-$0.34 (-0.24%)
Updated
Jul 31 closing price
Net Assets
188.57B
Interact to see
Advertisement

GMAPX vs VSMAX

GMAPX vs VSMAX Comparison Chart in %
View a ticker or compare two or three
VS
GMAPX vs. VSMAX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMAPX is a Hold and VSMAX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSMAX has more cash in the bank: 189B vs. GMAPX (1.01B). VSMAX pays higher dividends than GMAPX: VSMAX (1.21) vs GMAPX (0.56). GMAPX was incepted earlier than VSMAX: GMAPX (8 years) vs VSMAX (26 years). GMAPX (0.92) is less costly to investors than VSMAX (0.05). GMAPX is a more actively managed with annual turnover of: 162.00 vs. VSMAX (17.00). GMAPX has a lower initial minimum investment than VSMAX: GMAPX (0) vs VSMAX (3000). GMAPX annual gain was more profitable for investors over the last year : 27.88 vs. VSMAX (22.58). VSMAX return over 5 years is better than : 35.11 vs. GMAPX (4.48).
GMAPXVSMAXGMAPX / VSMAX
Total Expense Ratio0.840.051,680%
Annual Report Gross Expense Ratio0.920.051,840%
Fund Existence8 years26 years-
Gain YTD21.25014.588146%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.01B189B1%
Annual Yield % from dividends0.561.2147%
Returns for 1 year27.8822.58123%
Returns for 3 years41.3343.4295%
Returns for 5 years4.4835.1113%
Returns for 10 yearsN/A155.96-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BQLCX23.420.17
+0.73%
Bright Rock Quality Large Cap Instl
GSPQX20.020.12
+0.60%
Goldman Sachs US Eq Div and Premium C
GSIYX24.29N/A
N/A
Goldman Sachs GQG Ptnrs Intl Opps R6
CCWIX21.73-0.15
-0.69%
Baird Chautauqua International Gr Instl
RYOAX66.89-1.55
-2.26%
Rydex Biotechnology H